Physician profile
Nikole Stephens
NPI 1134583404
$2,794.95
in general payments reported to CMS, 2019-2025
25 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.25 · 2022: $540 · 2023: $1,122 · 2024: $630 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.14 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $616.90 | 2022-2024 | Bexsero, Arexvy, Shingrix |
| Abbvie INC. | $550.35 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Abbott Laboratories | $410.15 | 2022-2025 | Freestyle Libre 3, Infinity, Id Now Instrument |
| Pfizer INC. | $242.48 | 2023-2025 | |
| Lilly USA, LLC | $165.34 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Phathom Pharmaceuticals, INC. | $143.44 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $83.50 | 2023 | Veozah |
| Novo Nordisk INC | $69.54 | 2021-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $61.89 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $55.63 | 2023 | |
| Revance Therapeutics, INC. | $49.10 | 2025 | Daxxify |
| Corcept Therapeutics | $47.99 | 2025 | Korlym |
| Amgen INC. | $41.15 | 2022-2024 | Repatha, Otezla |
| Alk-Abello, INC | $34.12 | 2025 | Grastek, Odactra, Ragwitek |
| Janssen Pharmaceuticals, INC | $30.50 | 2024 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.68 | 2023 | Jardiance |
| Antares Pharma, INC. | $21.41 | 2022 | |
| Exact Sciences Corporation | $20.99 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $20.74 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.66 | 2022 | |
| Kaleo, INC. | $18.75 | 2023 | Auvi-Q |
| Galderma Laboratories, L.P. | $18.48 | 2023 | |
| Tris Pharma INC | $17.55 | 2024 | Dyanavel Xr |
| Hikma Pharmaceuticals USA | $15.40 | 2025 | Ryaltris |
| Tolmar, INC. | $15.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikole Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.